Want to see AU:PER full AI Analyst Report?
Top Page
Percheron Therapeutics
(Sydney:PER)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.01
▲(0.00% Upside)
Action:Reiterated
Date:08/04/26
The score is driven primarily by weak financial performance: a pre-revenue profile with widening losses, negative gross profit, and accelerating cash burn that increases funding risk. Low leverage modestly reduces solvency risk, but it does not offset equity erosion and negative free cash flow. Technical and valuation inputs are limited or unattractive due to missing indicators and a negative P/E.
Positive Factors
Low Financial Leverage
Very low debt relative to equity provides a durable solvency cushion that reduces near-term default risk and preserves access to borrowing or partnership options. This structural conservatism gives management flexibility to finance R&D or delay dilutive funding events.
Negative Factors
Pre-revenue with widening operating losses
Sustained pre-revenue status combined with materially widening losses means long reliance on external funding and clinical success to create value. Over 2-6 months this structural reality increases execution and financing risk and limits ability to self-fund R&D progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Very low debt relative to equity provides a durable solvency cushion that reduces near-term default risk and preserves access to borrowing or partnership options. This structural conservatism gives management flexibility to finance R&D or delay dilutive funding events.
Read all positive factors
Percheron Therapeutics (PER) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$6.09M
Dividend YieldN/A
Average Volume (3M)2.49M
Price to Earnings (P/E)―
Beta (1Y)0.43
Revenue GrowthN/A
EPS Growth49.10%
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,522,412,700
10 Day Avg. Volume2,742,659
30 Day Avg. Volume2,485,493
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.02
Price to Sales (P/S)0.00
P/FCF Ratio-0.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)AU$858.00K
Percheron Therapeutics Business Overview & Revenue Model
Company Description
Percheron Therapeutics Limited, an Australian enterprise established in 2000 with its headquarters in Melbourne, is dedicated to the research and development of groundbreaking antisense pharmaceuticals. Formerly known as Antisense Therapeutics Lim...
How the Company Makes Money
null...
Percheron Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
56
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -50.97K | -67.98K | -79.42K | -95.20K | -89.22K | -103.32K |
| EBITDA | -10.94M | -16.27M | -11.84M | -13.25M | -7.52M | -8.58M |
| Net Income | -9.49M | -14.92M | -11.92M | -11.38M | -5.81M | -8.06M |
Balance Sheet | ||||||
| Total Assets | 7.90M | 12.44M | 14.53M | 12.84M | 22.44M | 7.00M |
| Cash, Cash Equivalents and Short-Term Investments | 4.46M | 10.17M | 11.87M | 10.97M | 19.23M | 6.02M |
| Total Debt | 10.68K | 25.86K | 39.87K | 142.10K | 227.40K | 306.85K |
| Total Liabilities | 763.70K | 2.43M | 5.17M | 2.87M | 1.30M | 1.27M |
| Stockholders Equity | 7.14M | 10.00M | 9.36M | 9.98M | 21.14M | 5.73M |
Cash Flow | ||||||
| Free Cash Flow | -9.78M | -15.65M | -10.12M | -8.18M | -7.81M | -5.84M |
| Operating Cash Flow | -9.78M | -15.64M | -10.12M | -8.15M | -7.81M | -5.83M |
| Investing Cash Flow | -3.08M | -7.24K | -3.61K | -29.29K | -3.91K | -8.35K |
| Financing Cash Flow | -70.82K | 13.95M | 11.02M | -85.30K | 21.02M | 7.80M |
Percheron Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$17.23M | 23.33 | 1.66% | 6.67% | 2.11% | -64.71% | |
55 Neutral | AU$62.10M | -15.87 | -1.67% | ― | 15.21% | -141.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | AU$5.81M | 0.35 | 93.89% | ― | -29.95% | ― | |
42 Neutral | AU$6.09M | -0.48 | -110.74% | ― | ― | 49.10% | |
42 Neutral | AU$20.02M | -5.07 | 4388.00% | ― | -53.90% | 57.52% | |
41 Neutral | AU$18.50M | -3.22 | -29.05% | ― | 6.14% | -20.00% |
* Healthcare Sector Average
AU:PER
Percheron Therapeutics
0.01
0.00
0.00%
AU:CAN
Cann Group
0.01
>-0.01
-28.57%
AU:LGP
Little Green Pharma Ltd.
0.08
-0.04
-31.82%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-31.82%
AU:IDT
IDT Australia Limited
0.05
-0.03
-36.99%
AU:VIT
Cronos Australia Ltd.
0.03
-0.04
-60.61%
Percheron Therapeutics Corporate Events
Percheron Advances Lead Cancer Drug Minperstobart and Raises $2.2m for New Trial
Jul 30, 2026
Percheron Therapeutics reported continued progress in the June quarter as it advances its lead oncology candidate HMBD-002 toward mid-stage trials. The World Health Organization has granted the drug the provisional international non-proprietary na...
Percheron Completes Manufacture of HMBD-002 Drug Substance for 2026 Trial
Jun 16, 2026
Percheron Therapeutics has completed manufacturing of a new batch of HMBD-002 drug substance, produced under a license agreement by Hummingbird Bioscience, with testing confirming that quality attributes meet expected standards. Final release and ...
Percheron Therapeutics Issues New Tranche of Unquoted Equity Securities
Jun 1, 2026
Percheron Therapeutics has issued 13.75 million unquoted options under the ASX code PERAQ, exercisable at A$0.01 and expiring on April 15, 2028, alongside a further 13.75 million unquoted securities in a new class to be confirmed. The move, execut...
Percheron Therapeutics Plans Issue of 13.75 Million Options to Bolster Capital
May 29, 2026
Percheron Therapeutics has notified the ASX of its intention to issue up to 13,750,000 options, each exercisable at $0.01 and expiring on April 15, 2028. The options are proposed to be issued on June 1, 2026, as part of a placement or other type o...
WHO assigns proposed nonproprietary name to Percheron’s cancer drug HMBD-002
May 26, 2026
Percheron Therapeutics announced that the World Health Organization has selected “minperstobart” as the proposed international nonproprietary name for its investigational VISTA-targeting cancer therapy HMBD-002. The company expects the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.